Managing Idiopathic Thrombocytopenic Purpura

This information was originally presented on September 15, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this activity, participants should be able to:

  • Identify the challenges associated with the diagnosis and management of ITP
  • Discuss the first-line and second-line therapies for the management of ITP
  • Outline the mechanism of action of recently approved thrombopoietic agents
  • Summarize the data from clinical trials evaluating thrombopoietic agents for the treatment of refractory ITP
Additional information

Supported by educational grants from Genentech; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Otsuka America Pharmaceutical, Inc.; and sanofi-aventis U.S.

Course summary
Available credit: 
  • 0.50 Participation
  • 0.50 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician
Course opens: 
Course expires: 

Eric H. Kraut, MD
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute

Available Credit

  • 0.50 Participation
  • 0.50 Nurse
  • 0.50 Pharmacist
  • 0.50 Physician


Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader for certificate viewing/printing